Shenzhen Salubris Pharmaceuticals Co., Ltd.
SZSE:002294.SZ
29.64 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 3,365.343 | 3,482.011 | 3,058.392 | 2,738.562 | 4,470.466 | 4,651.876 | 4,153.777 | 3,833.49 | 3,477.693 | 2,882.645 | 2,327.484 | 1,828.882 | 1,474.885 | 1,297.767 | 849.598 | 527.17 | 349.435 | 203.144 |
Cost of Revenue
| 1,065.462 | 993.612 | 793.279 | 847.697 | 964.366 | 943.673 | 785.056 | 949.879 | 912.288 | 764.854 | 564.619 | 465.422 | 559.862 | 555.592 | 376.41 | 259.36 | 185.872 | 107.099 |
Gross Profit
| 2,299.881 | 2,488.399 | 2,265.113 | 1,890.865 | 3,506.1 | 3,708.203 | 3,368.721 | 2,883.611 | 2,565.404 | 2,117.791 | 1,762.864 | 1,363.46 | 915.022 | 742.175 | 473.187 | 267.809 | 163.563 | 96.045 |
Gross Profit Ratio
| 0.683 | 0.715 | 0.741 | 0.69 | 0.784 | 0.797 | 0.811 | 0.752 | 0.738 | 0.735 | 0.757 | 0.746 | 0.62 | 0.572 | 0.557 | 0.508 | 0.468 | 0.473 |
Reseach & Development Expenses
| 376.371 | 533.75 | 357.368 | 371.195 | 763.497 | 407.477 | 327.054 | 224.273 | 175.765 | 121.18 | 127.608 | 112.328 | 77 | 66.596 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 102.809 | 62.37 | 60.738 | 48.138 | 51.114 | 52.467 | 53.098 | 43.567 | 44.656 | 27.048 | 22.527 | 32.832 | 16.411 | 12.559 | 53.482 | 29.887 | 21.16 | 13.427 |
Selling & Marketing Expenses
| 606.686 | 1,094.427 | 1,035.866 | 899.198 | 1,576.269 | 1,345.644 | 1,155.732 | 852.075 | 775.144 | 713.013 | 594.467 | 453.183 | 332.303 | 256.385 | 168.877 | 111.4 | 65.161 | 44.088 |
SG&A
| 1,267.829 | 1,156.797 | 1,096.604 | 947.336 | 1,627.383 | 1,398.111 | 1,208.83 | 895.641 | 819.8 | 740.061 | 616.994 | 486.014 | 348.715 | 268.945 | 222.359 | 141.287 | 86.321 | 57.515 |
Other Expenses
| 7.616 | 165.366 | 233.995 | 203.955 | 229.045 | -13.716 | 0.7 | 22.048 | 13.289 | 10.907 | 15.065 | 20.807 | 8.387 | 2.777 | 4.536 | 3.105 | 0.616 | -0.664 |
Operating Expenses
| 1,651.816 | 1,855.913 | 1,687.968 | 1,522.486 | 2,619.925 | 2,014.885 | 1,710.71 | 1,279.38 | 1,106.622 | 943.704 | 809.209 | 647.532 | 461.594 | 344.709 | 223.013 | 141.709 | 86.586 | 57.685 |
Operating Income
| 655.976 | 727.436 | 586.195 | 348.723 | 846.081 | 1,719.962 | 1,714.623 | 1,630.848 | 1,478.478 | 1,207.186 | 967.764 | 729.794 | 466.774 | 412.72 | 245.703 | 123.527 | 76.151 | 37.331 |
Operating Income Ratio
| 0.195 | 0.209 | 0.192 | 0.127 | 0.189 | 0.37 | 0.413 | 0.425 | 0.425 | 0.419 | 0.416 | 0.399 | 0.316 | 0.318 | 0.289 | 0.234 | 0.218 | 0.184 |
Total Other Income Expenses Net
| -14.215 | -13.711 | 13.647 | -22.478 | 5.265 | -13.716 | 0.7 | 20.295 | 13.01 | 10.177 | 8.67 | 20.497 | 7.787 | 2.768 | 3.65 | 0.533 | 0.438 | -0.664 |
Income Before Tax
| 641.761 | 713.725 | 599.842 | 56.743 | 851.346 | 1,706.246 | 1,715.323 | 1,650.475 | 1,491.488 | 1,217.363 | 976.434 | 750.288 | 474.56 | 415.488 | 249.352 | 126.632 | 76.59 | 36.667 |
Income Before Tax Ratio
| 0.191 | 0.205 | 0.196 | 0.021 | 0.19 | 0.367 | 0.413 | 0.431 | 0.429 | 0.422 | 0.42 | 0.41 | 0.322 | 0.32 | 0.293 | 0.24 | 0.219 | 0.18 |
Income Tax Expense
| 60.932 | 79.507 | 71.52 | 6.608 | 169.505 | 251.665 | 278.442 | 260.436 | 221.814 | 173.979 | 143.174 | 114.736 | 69.112 | 59.978 | 33.673 | 9.69 | 3.452 | 2.428 |
Net Income
| 580.066 | 637.091 | 533.727 | 60.865 | 715.201 | 1,458.223 | 1,451.887 | 1,396.414 | 1,265.92 | 1,042.297 | 830.417 | 635.168 | 405.249 | 355.314 | 215.747 | 116.942 | 73.138 | 34.239 |
Net Income Ratio
| 0.172 | 0.183 | 0.175 | 0.022 | 0.16 | 0.313 | 0.35 | 0.364 | 0.364 | 0.362 | 0.357 | 0.347 | 0.275 | 0.274 | 0.254 | 0.222 | 0.209 | 0.169 |
EPS
| 0.52 | 0.58 | 0.5 | 0.059 | 0.69 | 1.39 | 1.39 | 1.33 | 1.21 | 1 | 0.79 | 0.61 | 0.39 | 0.34 | 0.25 | 0.15 | 0.093 | 0.052 |
EPS Diluted
| 0.52 | 0.58 | 0.5 | 0.059 | 0.69 | 1.39 | 1.39 | 1.33 | 1.21 | 1 | 0.79 | 0.61 | 0.39 | 0.34 | 0.25 | 0.15 | 0.093 | 0.052 |
EBITDA
| 1,050.526 | 1,046.421 | 914.637 | 377.103 | 1,096.717 | 1,813.574 | 1,855.323 | 1,774.405 | 1,527.501 | 1,237.429 | 1,018.969 | 757.425 | 485.162 | 435.395 | 263.778 | 136.723 | 84.203 | 41.802 |
EBITDA Ratio
| 0.312 | 0.314 | 0.35 | 0.217 | 0.248 | 0.405 | 0.44 | 0.462 | 0.443 | 0.431 | 0.438 | 0.419 | 0.334 | 0.342 | 0.315 | 0.261 | 0.241 | 0.209 |